title: Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97.
abstract: In November 1996, 11 lots of one U.S. manufacturer's 1996-97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer's vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996-97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer > or = 1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 (p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.
authors.affiliation: Influenza Branch, Centers for Disease Control and Prevention, Mail stop A-32, 1600 Clifton Road, Atlanta, GA 30333, USA.
authors.forename: C
authors.initials: C
authors.lastname: Buxton Bridges
authors.forename: K
authors.initials: K
authors.lastname: Fukuda
authors.forename: R C
authors.initials: RC
authors.lastname: Holman
authors.forename: A M
authors.initials: AM
authors.lastname: De Guzman
authors.forename: R A
authors.initials: RA
authors.lastname: Hodder
authors.forename: I H
authors.initials: IH
authors.lastname: Gomolin
authors.forename: G K
authors.initials: GK
authors.lastname: Galligan
authors.forename: H B
authors.initials: HB
authors.lastname: Leib
authors.forename: R J
authors.initials: RJ
authors.lastname: Gallo
authors.forename: H L
authors.initials: HL
authors.lastname: Regnery
authors.forename: N H
authors.initials: NH
authors.lastname: Arden
authors.forename: N J
authors.initials: NJ
authors.lastname: Cox
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D009735:Nursing Homes; D013997:Time Factors; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines